Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday.
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67 million.
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Ardelyx (NASDAQ:ARDX) shares moved upwards by 53.3% to $1.87 during Thursday’s regular session. Trading volume for Ardelyx’s…
Looking Into Ardelyx’s Recent Short Interest
Ardelyx's (NASDAQ:ARDX) short percent of float has fallen 23.89% since its last report. The company recently reported that it has 7.34 million shares sold short, which is 3.95% of all regular shares that are available for trading.
S&P 500 Down 1%; Crude Oil Drops Sharply
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday.
Piper Sandler Upgrades Ardelyx to Overweight, Raises Price Target to $8
Piper Sandler analyst Christopher Raymond upgrades Ardelyx (NASDAQ:ARDX) from Neutral to Overweight and raises the price target from $3 to $8.
Reported Late Wednesday, Ardelyx Announces FDA Advisory Committee Votes 9-To-4 That The Benefits Of XPHOZAH Outweigh Its Risks For The Control Of Serum Phosphorus In Adult Patients With Chronic Kidney Disease On Dialysis
The Advisory Committee voted 9:4 in favor of XPHOZAH as a monotherapy and 10:2 in favor of XPHOZAH in combination with phosphate binders
The Office of New Drugs is expected to provide a response to Ardelyx's appeal
FDA Signals Unclear Clinical Benefits Of Ardelyx’s Kidney Disease Candidate
The FDA’s Cardiovascular and Renal Drugs Advisory Committee is scheduled to meet Wednesday, November 16, to review Ardelyx Inc (NASDAQ:ARDX) Xphozah (tenapanor)…